References
1. Renu K., Abilash V.G., Tirupathi Pichiah P.B., Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy – an update. Eur J Pharmacol. 2018; 818: 241–53.
2. Gendlin G.E., Emelina Е.I., Nikitin I.G., Vasyuk Yu. А. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Rossiyskiy kardiologicheskiy zhurnal [Russian journal of cardiology]. 2017; 3 (143): 145–54. (in Russian)
3. Said R., Nickolich M., Lenihan D.J., Tsimberidou A.M. Cardiotoxicity of anticancer therapies. Cardio-Oncology: Clin Overlap Cancer Heart Dis 5 (February). 2017: 15–42.
4. Tan L.L., Lyon A.R. Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med. 2018; 20 (7).
5. Kulyova1 S.A., Semiglazova T.Yu., Zvyagintseva D.A., Belogurova M.B., Ivanova S.V. Cardiovascular complications of antineoplastic therapy In children. Pediatr [Pediatrician]. 2017; 8 (3): 130–41. (in Russian)
6. Golubtsov O.U., Tyrenko V.V., Polyakov A.S., Makiev R.G, Shakhnovich P.G. Prospects of antioxidant therapy in prevention of cardotoxicity caused by the use of anthracycline antibiotics. Literature review. Vestnik national`nogo medico-khirurgicheskogo Tsentra im. N.I. Pirogova [Bulletin of Pirogov National Medical & Surgical Center]. 2017; (2): 121–5. (in Russian)
7. Leong D.P., Caron F., Hillis C., Duan A., Healey J.S., Fraser G., Siegal D. The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis. Blood. 2016; 138–40.
8. Shuikova K.V., Emelina E.I., Gendlin G.E., Storozhakov G.I. Cardiotoxicity of modern chemotherapeutic drugs. Atmosfera. Novosti kardiologii [Atmosphere. Cardiology news]. 2012; (3): 9–19. (in Russian).
9. Tanindi A., Ugurlu M., Tore H.F. Blood pressure morning surge, exercise blood pressure response and autonomic nervous system. Scand Cardiovasc J. 2015; 49 (4): 220–7.
10. Touyz R.M., Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis. Oncol. 2018; 2: 13.
11. Plokhova E., Doundoua D. Cardiooncology. Basic Principles of Prevention and Treatment of Cardiotoxicity in Cancer Patients. Journal of Clinical Practice. 2019; 10 (1): 32–42. DOI: https://doi.org/10.17816/clinpract10130–40
12. Cappetta D., Urbanek K., Rossi F., De Angelis A. Anthracycline cardiotoxicity: new actors on the stage. Transl Cancer Res. 2018; 7 (S5): S580–S583.
13. Moazeni S., Cadeiras M., Yang E.H., Deng M.C., Nguyen K.-L. Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient specific care. Clin Transl Med. 2017; 6 (1).
14. Gumerova K.S., Sakhautdinova G.M., Polyakova I.M. Antitumour drug induced cardiovascular toxicity and current tumour treatment methods. Kreativnaya khirurgiya I onkologiya [Creative surgery and oncology].2019; (9): 285–92. (in Russian)
15. Kalyuta T.Yu., Kiselev A.R., Bazarbaeva A.Kh. Medication cardiotoxicity: potential of prevention and correction (review). Saratovskiy nauchno-meditsinskiy zhurnal [Saratov Scientific and Medical Journal]. 2020; 16 (3): 736–43. (in Russian)
16. Vasyuk Yu.A., Shkolnik E.L., Nesvetov V.V., Shkolnik L.D., Varlan G.V., Pilshchikov A.V. Anthracycline cardiotoxicity: Prospects for using ivabradine. Kardiosomatica [Cardiosomatics]. 2012; 3 (4): 65–9. (in Russian)
17. Ibragimova A.A., Emelina E.I., Gendlin G.E., Nikitin I.G. Ability to prevent and treat the cardiovascular system damages, caused by the use of anti-cancer drugs. Rossiyskiy meditsinskiy zhurnal [Medical Journal of the Russian Federation]. 2018; (24): 316–323. (in Russian)
18. Tamargo J., Caballero R., Delpón E. Cancer Chemotherapy and Cardiac Arrhythmias: A Review. Drug Saf. 2015; 38: 129–52.
19. Piccart-Gebhart M., Holmes E., Baselga J., De Azambuja E., Dueck A.C., Viale G., Zujewski J.A., Goldhirsch A., Armour A., Pritchard K.I., et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016; 34: 1034–42.
20. Nowsheen S., Aziz K., Park J.Y., Lerman A., Villarraga H.R., Ruddy K.J., Herrmann J. Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction. J Am Heart Assoc. 2018; 7.
21. Grassi G., Ram V.S. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens. 2016; 10 (5): 457–66.
22. Lenneman C.G., Sawyer D.B. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016; 118 (6): 1008–20.
23. Mitry M.A., Edwards J.G. Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasc. 2016; 10: 17–24.
24. Nicol M., Baudet M., Cohensolal A. Comorbidities subclinical left ventricular dysfunction during chemotherapy comorbidities. Cardiac Failure Review. 2019; 942: 31–6.
25. Jain D., Ahmad T., Cairo M., Aronow W. Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. Ann Transl Med. 2017; 5 (17): 348.
26. McGowan J.V, Chung R., Maulik A., Piotrowska I., Walker J.M., Yellon D.M. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017; 31 (1): 63–5.
27. Santos D.S., Goldenberg R.C.S. Doxorubicin-induced cardiotoxicity: from mechanisms to development of efficient therapy (Chapter 1). Cardiotoxicity: Intech Open, 2018.